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3D cancer models 
Bioprinting 
Personalized medicine 
a b s t r a c t 
After cardiovascular disease, cancer is the leading cause of death worldwide with devastating health and eco- 
nomic consequences, particularly in developing countries. Inter-patient variations in anti-cancer drug responses 
further limit the success of therapeutic interventions. Therefore, personalized medicines approach is key for 
this patient group involving molecular and genetic screening and appropriate stratification of patients to treat- 
ment regimen that they will respond to. However, the knowledge related to adequate risk stratification methods 
identifying patients who will respond to specific anti-cancer agents is still lacking in many cancer types. Re- 
cent advancements in three-dimensional (3D) bioprinting technology, have been extensively used to generate 
representative bioengineered tumor in vitro models, which recapitulate the human tumor tissues and microen- 
vironment for high-throughput drug screening. Bioprinting process involves the precise deposition of multiple 
layers of different cell types in combination with biomaterials capable of generating 3D bioengineered tissues 
based on a computer-aided design. Bioprinted cancer models containing patient-derived cancer and stromal cells 
together with genetic material, extracellular matrix proteins and growth factors, represent a promising approach 
for personalized cancer therapy screening. Both natural and synthetic biopolymers have been utilized to support 
the proliferation of cells and biological material within the personalized tumor models/implants. These models 
can provide a physiologically pertinent cell–cell and cell–matrix interactions by mimicking the 3D heterogeneity 
of real tumors. Here, we reviewed the potential applications of 3D bioprinted tumor constructs as personalized 






































Despite extensive research, the survival and the quality of life with
ertain types of cancer are still poor, accounting for millions of deaths
orldwide [1–3] . The response to cancer treatments varies substantially
etween patients and it is associated with significant economic burden,
articularly in developing countries [ 4 , 5 ]. Considerable progress has
lready been made in developing novel therapeutic interventions for
ancer including immunotherapies, therapeutic peptides [6] , Notch tar-
eted strategies [7] and other targeted therapies that have transformed
he field of oncology. The gold standard treatment for the vast majority
f cancers includes chemotherapeutic agents; however, the response to
hese treatments is still variable amongst patients, particularly for poorly
haracterized cancers. Hence, the “one ‐size ‐fits ‐all ” treatment approach
an have limited effectiveness, identifying a clinical need for more per-
onalized/precision treatment regimens specific to an individual or a
ubset of patients. In addition to the overall response, drug efficacy∗ Corresponding authors. 
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 8 , 9 ]. This is likely due to tumor heterogeneity, the presence of cancer
tem cells and cancer cell plasticity [ 10 , 11 ], indicating the need for a
ombination of multiple drug treatments including targeted therapies.
n support of this, a study investigating various treatment options for
5 different tumor types demonstrated that patients who were treated
ith targeted therapy had a significantly better overall response rate and
rogression free survival [12] . Similarly, determining the most suitable
herapeutic dose and timing of the treatment, is key in managing cancer
atients without debilitating adverse effects. 
Unlike i n vivo models , in vitro cancer models are simplified ap-
roaches to study cancer mechanisms and behavior, and to examine
he effects of established and novel anti-cancer agents. It is now well es-
ablished that the soluble factors released from cancer and stromal cells
an influence the cell viability/proliferation, cell-cell adhesion, cell mi-
ration, mechanotransduction, and signaling of cells within the tumor
issue, which is difficult to replicate in traditional 2D cell culture mod-A. Hasan). 
uary 2021 
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t  ls. Recent developments have demonstrated that tumors can success-
ully grow across the 3D microenvironment/extracellular matrix (ECM),
esulting in gradient exposure of cancer cells to oxygen and nutrients
13] . Hypoxia or low oxygen can lead to excessive cell proliferation
ithin tumor tissue; highly proliferative cancer cells can generate lo-
al hypoxia within tumors under in vivo conditions increasing the per-
entage of non-proliferating viable hypoxic tumor and/or cancer stem
ells [14] . These features of tumor tissue are not recapitulated in 2D
onolayer cultures [15] and hence 3D cancer models have better phys-
ological relevance for testing drug treatments and understanding dis-
ase mechanisms. Amongst the recent 3D models, utilization of spher-
cal models has shown the most promise, which in combination with
ppropriate microenvironment and biomaterials could revolutionize in
itro personalized drug screening. The most frequently utilized 3D can-
er models for drug testing include multicellular tumor spheroid model
MCTS), multilayered cell cultures, organotypic slices of cancer tissue,
nd cell seeded scaffolds [16] . Over the past few decades, printing tech-
ology has progressed from 2D printing to an additive process capable
f producing 3D shapes. Recently, 3D bioprinting, an additive manu-
acturing spinoff technology, has been successfully used in laboratories
orldwide to create pulsating 3D tissue constructs [17] . The bioprint-
ng field has had substantial technological advances in the last five years
ecoming the most promising approach for developing 3D constructs of
umor tissue that can be used as models for studying cancer biology
nd screening anticancer agents [18] . The major advantage of bioprint-
ng is the ability to precisely control and define the desired structure of
he tissue construct according to the 3D design [19] . Unlike other ap-
roaches for developing 3D cancer models, multiple cells (both cancer
nd normal) can be deposited with microscale precision by 3D bioprint-
ng, therefore closely reconstituting a cancer microenvironment [18] .
any researchers have been successful in developing bioprinted breast
20] , brain [21] , skin [22] , pancreatic [23] , and other cancer models
or this purposes. 
In this review, we provide a comprehensive summary of the collec-
ive findings in relation to various bioprinted cancer models utilized for
hemotherapeutic drug screening. 2D and 3D cancer models are criti-
ally evaluated and comprehensively compared, in terms of their ability
o recapitulate physiological tumors and their microenvironment. Vari-
us strategies used for bioprinting of 3D cancer models including inkjet,
icro extrusion, and laser ablation technologies as well as cancer and
tromal bioinks, and biomaterials, are discussed. This review clearly out-
ines current challenges and prospects for 3D bioprinting technologies
n cancer research by focusing on the clinical application of these tech-
ologies for chemotherapeutic drug screening and the development of
ersonalized treatment regimens for cancer patients. 
. Precision anticancer drug screening 
Cancer patients display a high degree of inter-patient variation in
erms of clinical outcomes, prognosis, and response or tolerance to med-
cation [24] . Thus, the need for prognostic preclinical models capable of
dentifying the most suitable treatment regimens for individual patients
s growing rapidly. This personalized approach could enable better re-
ponse to treatment with reduced incidence of adverse effects [ 25 , 26 ].
he response to chemotherapy treatments depends on molecular sub-
ypes of tumors, cancer stage, comorbidities, genomic background and
atient’s tolerance to treatments, which can vary significantly between
atients. One of the effective approaches to develop personalized treat-
ent is to replicate the disease in laboratory using 3D cell models based
n patient-derived tumors following debulking surgery, and test var-
ous treatment options for the specific cancer phenotype. While this
pproach can test the effectiveness of the treatment, it might not be
ble to determine the adverse and off target, effects. Precision medicine
pproach does not rely on “one-fits-all ” model but rather investigates
pecific therapeutic interventions suitable for each individual patient
hat the conventional and general in vivo and in vitro models cannot2 e necessarily used for. Patient-derived cell-based tumor organoids and
enografts have shown some promise in advancing precision medicine,
nabling the development of personalized chemotherapeutic regimens
27] . Developments in this field resulted in the utilization of bioprinting
or anticancer drug screening by generating physiologically relevant 3D
ancer or tumor models hence providing a platform of controlled envi-
onment and physiologically relevant models [28] . 
Therefore, testing of multiple chemotherapeutic drugs on patient-
erived bioprinted cancer models could identify the most effective com-
ination of chemotherapeutic drug candidates for a individual patient.
hese bioprinted cancer models can also complement human clinical tri-
ls where the effectiveness and mechanisms of drug candidates can be
ested on individual basis taking into the account not just the molecular
ubtype of the tumor but also the differences in age, sex and ethnicity as
ell as identifying the most optimal doses of chemotherapeutic agents
29] . 
. Two- and three-dimensional cell culture systems in cancer 
esearch 
2D cancer models have contributed significantly to our basic under-
tanding of cancer biology over the past several decades. These simple
ancer models have also played a significant role in pharmaceutical test-
ng. However, considerable differences in the molecular signaling, pro-
ein and gene expression, cell phenotype, cell migration, cell viability,
ell proliferation and drug response, have been observed between 2D
nd 3D cancer models [ 5 , 30 , 31 ]. 3D systems, especially those based on
ell-seeded hydrogel platforms, secrete cytokine and angiogenic factors
or longer period of time than a monolayer 2D culture [ 32 , 33 ]. Also, the
ell secreted biomolecules tend to be displaced during media replace-
ent hence limiting the ability of a 2D cell culture system to provide the
ost optimal environment for cells to grow [34] . Furthermore, the lack
f adequate ECM to support and communicate with cancer cells can also
mpact on biological relevance of these in vitro systems [35] . Although
D cell models can offer some insight into cancer biology, the applica-
ility of the results should be interpreted with caution as molecular and
ellular interactions are not recapitulated, limiting our understanding
f the cell–cell and cell–ECM interactions. 
On the other hand, 3D cancer constructs represent physiological can-
er tissues better, in terms of tumor microenvironment and cellular be-
avior with characteristic spatial distribution of cells [36] . This has,
herefore, contributed significantly to the development of more reliable
ancer models that can be used for the screening of potential anticancer
gents and novel treatment regimens for various types of cancers [20] .
istopathological analyses of the tumors have confirmed that tumors
re 3D structures composed of heterogeneous population of cells includ-
ng cancer cells, cancer stem cells and healthy cells embedded within
tromal tissue [37] . Despite the large body of evidence, which supports
he knowledge that 3D models are more physiologically relevant than
D cultures [ 38 , 39 ], current pharmaceutical screening heavily relies on
ells cultured as monolayers due to low cost and ease of use. A number
f research studies have assessed the performance of human cells in 2D
r 3D culture systems to in vivo models. For example, 3D cell refine-
ents within organoids have shown potential as an alternative method
o study drug pharmacokinetics within the tumor tissue therefore ad-
ressing the gap in transition between 2D cell culture and animal mod-
ls [40] . These cell models can be overall divided into: (i) co-culture
ystems, (ii) multicellular spheroids, and (iii) cells loaded or cultured in
n ECM mimetic biopolymeric scaffold [ 41 , 42 ] ( Fig. 1 ). Within 3D cell
odels, both primary cancer cells isolated from patient tumor biopsies
r established cell lines can be utilized for the purpose of developing
epresentative human models for chemotherapeutic drug testing. Even
he simplest spheroid tumor models showed several advantages over
D cell culture systems. For instance, Grandis et al used 3D multicellu-
ar DU-145 prostate cancer cell line based spheroids that could effec-
ively simulate the prostate tumor microenvironment to evaluate the
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Fig. 1. Various in vitro cancer models used in chemotherapeutic screening. Evolution of cell-culture models from simple 2D to complex 3D bio-printed models. 
Conventional 2D monolayer culture, monolayer co-culture, cells grown over floating membranes, and cell monolayer sandwiched between membranes, are the 
commonly used 2D cancer models in research and drug screening. Cancer cells cultured in hydrogels, spheroid monoculture, spheroid co-culture, cancer/stromal 












































a  ytotoxic effects of ruthenium complexes [43] . The format chosen and
ts alterations depend on the purpose of the model. For example, for the
reliminary screening of an anticancer agent, a 2D cell culture system
omposed of a single type of cells would be sufficient. If the goal is to
est the efficacy of a chemotherapeutic agent in a heterogeneous tumor
nvironment, a spheroid model composed of cancer cells, cancer stem
ells, circulating tumor cells (CTCs) and different stromal cells should
e incorporated. However, to get a clear understanding of drug pene-
ration, anti-metastatic effect and clearance, a 3D model composed of
iopolymeric scaffolds, cancer cells and multiple types of stromal cells
ith vascular channels needs to be developed [44] . 
In pursue of personalized drug screening, multicellular organoids can
e generated using different types of patient-derived cells isolated from
iopsy tissues in a co-culture system capable of creating spheroids. The
ajor advantage of these spheroid systems is that the screening can be
erformed with very small quantities of chemotherapeutic candidates
45–47] . However, spheroid models cannot completely recapitulate the
ellular and microenvironmental heterogeneity of physiological tumor
issue where spatiotemporal variations in nutrients supplement, cell pro-
iferation and oxygenation often occur. A number of reports show that
ignificant difference between the 2D and 3D models in many of the
ajor physiological features of cancer cell culture, such as expression
f genes and proteins, cell migration and cell proliferation are very im-3 ortant factors in personalized chemotherapeutic screening [30] . Lastly,
D cancer models can be maintained in bioreactors where the cell cul-
ure parameters can be precisely regulated and monitored in real-time,
hich is not possible in static 2D cultures [48] . Therefore, creating het-
rogenous and physiologically related 3D cancer tissue constructs is ex-
ected to expand our understanding of the effects and mechanisms of
hemotherapeutic agents on the cancer growth, progression, metasta-
is and therapy response [49] . For high-throughput screening or tissue
ngineering, researchers tend to prefer automated approaches such as
hose employing 3D bioprinting. With the help of bioprinting, it is pos-
ible to generate cell laden cancer tissue constructs that can recapitulate
he features of various types of cancers, and used for drug screening and
reclinical testing [50] . 3D tumor constructs generated by 3D bioprint-
ng approaches have expressed characteristics of in vivo tumor tissues,
uch as high growth rates of cancer cells, aggressive invasiveness, angio-
enesis, metastasis, high resistance to anticancer drugs [18] . Moreover,
D bioprinted tumor constructs can supplement animal xenograft mod-
ls because they maintain cancer–stromal cell interactions. 
. An overview of 3D bioprinting 
3D bioprinting is an innovative biomanufacturing platform, which
llows the deposition of living cells, signaling molecules and biomate-
































































































































o  ials using computer-aided design (CAD) to generate tissue engineered
onstructs with highly controlled tissue architecture [ 51 , 52 ]. Bioprint-
ng technology can create graded macroscale architectures mimicking
he ECM, thereby enhancing the attachment and proliferation of differ-
nt cell types, simultaneously. 3D bioprinted constructs can effectively
imic the tumor microenvironment. Moreover, spatial control of matrix
roperties, ability to integrate perfusable vascular networks, automa-
ion and high-throughput testing abilities for determining metabolic,
nd toxicological properties are imperative features of bioprinted cancer
odels [18] . 
Utilizing bioprinting technology, many complex internal tissue struc-
ures including channels and stroma with varying dimensions can be
enerated [53] . Consequently, it is also possible to produce different
ayers of cells including normal tissue specific cells, connective tissues
nd cancer cells [54] . Some of the important factors influencing bio-
rinted cancer constructs are physicochemical properties of biomateri-
ls, their concentration/viscosity, features of cells, cell concentration,
rinting process, flow, printing time, extrusion pressure, crosslinking
echniques, post-processing, and cell culture conditions [55] . Many of
hese parameters need to be optimized to unveil the full potential of this
echnology [56] . At present, natural polymers like alginate [57] , gelatin
58] , collagen, fibrin and hyaluronic acid are widely used in bioprinting
59] . Similarly, many combinations of synthetic and naturally derived
ydrogels (E.g. Gelatin methacryloyl) are being used within bioinks to
rint robust tissue constructs [ 60 , 61 ]. Crosslinking is an essential step
n bioprinting enabling production of a bioprinted construct that is sta-
le under physiological conditions [62] . Stabilization and strengthening
f bioprinted constructs can be achieved through physical or chemical
rosslinking methods [63] . Chemical crosslinking methods can be based
n enzymes (e.g., mushroom tyrosinase for gelatin) [64] , tannic acid
for collagen crosslinking), and divalent cations such as calcium ions
for alginate) [65] . Physical crosslinking approaches including ultravi-
let (UV) -treatment (e.g., for gelatin methacryloyl (GelMA)) are also
eing used for stabilizing the cell-laden bioprinted constructs [66] . 
Based on instrumentation approaches, bioprinting approaches can be
lassified into droplet, extrusion and laser-based bioprinting depending
n their deposition mechanism [67] ( Fig. 2 -A). In droplet-based bio-
rinting approach, different energy sources including sound, temper-
ture, and electricity are used to produce bioink droplets in a high-
hroughput manner [ 68 , 69 ]. Extrusion based bioprinters consist of a
uid dispensing system for bioink extrusion and an automated robotic
ystem for accurately depositing bioink on the platform according to
he design. Recently, a rational integration of microfluidic systems with
xtrusion printing was adopted to attain rapid deposition of bioink
70] ( Fig. 2 -B). It is reasonable that the extrusion-related stress may alter
ell viability [ 71 , 72 ]. Laser-based bioprinting facilitates high-precision
atterning or fabrication of tissue constructs with the help of laser
nergy. In laser-assisted bioprinting (otherwise called biological laser
rinting, LAB), to generate vaporizing sacrificial layer, laser energy is
sed in the system to push a cargo to a receiving substrate (in nozzle-
ree bioprinting) [73] . Other methods used for bioprinting include mask
atterning with similar functionalities to silicon chip patterning pro-
ess ( Fig. 2 -C). Laser direct-write (LDW) bioprinting technique is an
xcellent technique for precisely encapsulating multiple types of cells
ithin microbeads [74] . These can be used to produce embryoid bod-
es (EBs) and MCTSs with desired manipulation of size and shape thus
howing tremendous potential as an innovative technique for generating
ioprinted tumor constructs [75] . 
.1. Utilization of cancer cells and stromal cells in 3D bioprinted cancer 
odels 
For generating a personalized bioprinted construct, patient-specific
ells and their microenvironment need to be recapitulated in the printed
onstruct. The success of the fabricated construct is highly dependent
n the selection of appropriate cells for bioprinting. Multiple types of4 ancer cells including primary cancer cells, CTCs, and stromal cells in-
luding fibroblasts, endothelial cells and stem cells can be used for print-
ng personalized tumor construct. Of note, stem cell-like phenotype was
bserved in personalized bioprinted tumor construct using a gelatin-
lginate-Matrigel bioink containing patient derived intrahepatic cholan-
iocarcinoma cells [78] . This construct also showed the expression of
everal cancer-associated biomarkers, cancer stem cell markers, and the
vidence of epithelial to mesenchymal transition (EMT). These stud-
es could further pave the way for bioprinting of multicellular patterns
ith patients own heterogenous cancer cells as a platform for testing
hemotherapeutic agents and hence the development of personalized
herapies [79] . 
Apart from cancer-associated cells, a bioprinted tumor construct
hould contain stromal cells to mimic a natural tumor microenviron-
ent of human tumors where the cancer cells are encapsulated within
ifferent types of healthy cells. Selection of these normal cells in bioinks
hould be based on the tumor characteristics and bioengineered accord-
ngly. For instance, a brain tumor construct should be based on patient-
erived tumor cells of interest mixed with surrounding healthy brain
ells including neurons, glial cells, astrocytes, and microvascular en-
othelial cells [ 80 , 81 ]. However, a breast cancer construct should be
esigned in such a way that patient-derived breast cancer cells are sur-
ounded by mammary epithelial cells, adipocytes, fibroblasts, and en-
othelial cells [ 82 , 83 ]. This approach facilitates recapitulation of the
umor type as well as the target tissue. 
.2. Bioinks for cancer bioprinting 
Bioinks are the building blocks of bioprinted constructs, which are
enerally composed of a suitable hydrogel, multiple types of cells, nutri-
nts, and growth factors. The hydrogels used in bioinks should be bio-
ompatible, and their gelation should be easily controllable [67] . More-
ver, these biopolymeric hydrogels should mimic structural, physico-
hemical, and biological properties of ECM to provide representative
umor microenvironment within the constructs. Biopolymers such as al-
inate, collagen, and agarose are widely used matrices for bioink due
o their low cytotoxicity, high water content and innate biocompatibil-
ty favoring cell adhesion, proliferation, differentiation, and maturation
 84 , 85 ]. Viscosity of bioinks is a critical factor that determine the print-
bility and quality of printed tumor constructs, which is related to the
hemical components and concentration of biopolymer used in bioinks
 86 , 87 ]. Crosslinkability of biopolymers used in bioink is another impor-
ant factor that can impact the reliability of printed construct. Sodium
lginate with Ca 2 + or other divalent cations are commonly used due
o fast gelation and minimum adverse effects on cells [88–90] . In or-
er to improve cell proliferation in bioprinted construct, alginate can
e combined with other bioactive hydrogels like collagen [ 91 , 92 ]. Pho-
ocrosslinkable hydrogels are another advancement in bioprinting. A
ethacrylated form of gelatin (GelMA), is one of the most successful
hotocrosslinkable hydrogel used in bioprinting [93–96] . In addition to
he importance of selecting adequate bioinks and crosslinking methods
or generation of viable bioprinted cancer models, the methodology of
ell integration is also critical, which requires preparation of cancer and
tromal bioinks separately. 
Cancer bioink: Cancer bioinks are composed of patient-derived can-
er cells (e.g. primary cancer cells, cancer stem cells, CTCs, cancer-
ssociated fibroblasts, CAF), suitable biopolymer (e.g. GelMA, alginate,
yaluronic acid and collagen), growth factors (EGF, FGF) and other nu-
rients (e.g. cell culture medium). For this purpose, a non-globular pro-
ein, fibrin, important for blood clotting [97] , and a gelatinous ECM
rotein secreted by the mouse sarcoma cells, Matrigel [98] , are widely
sed. These hydrogel matrices provide an optimum microenvironment
or cancer cell proliferation and tumorigenesis to generate a tumor tis-
ue with relatively similar structural as well as functional features to in
ivo tumors [ 99 , 100 ]. Schiele et al. reported successful encapsulation
f neural stem cells, pulmonary artery endothelial cells, myoblasts, der-
R. Augustine, S.N. Kalva, R. Ahmad et al. Translational Oncology 14 (2021) 101015 
Fig. 2. Various methods of bioprinting used in the development of bioengineered cancer tissues. (A) Components of inkjet, microextrusion based and laser-assisted 
bioprinters. (B) A scheme showing the multi-cartridge module based Integrated Tissue Organ Printer (ITOP) system consisting of stage/controller, dispensing module 
with pressure controller and a closed chamber. (C) Schematic diagram of a two-step 3D bioprinting method in which hiPSC-HPCs were patterned by the first digital 
mask followed by the patterning of supporting cells using a second digital mask. Figure A is reproduced from [52] with the permission of Springer Nature. Figure B 




































i  al fibroblasts, breast cancer cells within Matrigel TM -based constructs
101] . Recent studies showed that the presence of CTCs, capable of dis-
eminating cancer cells to distant locations are the major contributors
o the development of metastatic cancer [102] . Hence, it is important
o incorporate these cells within cancer bioinks, facilitating the inves-
igations into anti-metastatic effects of chemotherapeutic agents [103] .
imilarly, cancer stem cells consist of a small percentage of the tumors
nd are highly tumorigenic and treatment resistant [ 6 , 104 , 105 ], there-
ore incorporating these cell types within tumor construct will provide a
etter insight into treatment response. In order to develop personalized
umor constructs for precision drug screening, these heterogeneous pop-
lation of cancer cells should be present within bioprinted cancer con-
tructs before chemotherapeutic combinations of treatments are tested
54] . However, the most challenging aspects of creating heterogenous
ancer constructs include: prompt isolation of sufficient number of cells,
aintenance of these heterogeneous group of primary cells, subsequent
ioprinting and rapid testing with drug candidates that will enable se-
ection of the most appropriate chemotherapy. 5 Stromal bioinks: In addition to primary cancer cells, tumor tissue is
lso composed of heterogeneous group of healthy stromal cells includ-
ng endothelial cells, mesenchymal/hematopoietic stem cells, fibrob-
asts and other tissue specific cells [ 106 , 107 ]. Similar to cancer bioinks,
oth natural and synthetic polymers have been used for creating stromal
ioinks including hydrogel matrices [108] . In order to recapitulate the
icroenvironment of physiological stroma of tumor tissue within bio-
rinted constructs, preferably, patient-derived primary cells from the
umor tissue should be isolated, cultured and mixed with the hydrogel
o generate the bioink rather than using biobanked primary cells and
ell line. Nevertheless, this is not always feasible, hence the most suit-
ble biobanked stromal cells should be selected for the tumor type. In
ivo , endothelial cells or endothelial progenitor cells are recruited by
umor immune cells and others to initiate tumor angiogenesis through
n array of secreted signaling molecules. Generally, tumor blood vessels
ave special features including extensive branching and loose intercel-
ular junctions making them leakier than normal blood vessels. Thus,
ncorporating endothelial or endothelial progenitor cells along with key





























































































































g  ngiogenic factors such as VEGF or EGF in stromal bioink is crucial for
ecapitulating tumor growth [109] . Nevertheless, generating vascular-
ze tumor construct still remains a challenge in bioengineering. 
.3. 3D bioprinting, in vitro maturation and characterization of bioprinted 
onstruct 
Briefly, the process of bioprinting starts with the CAD design of the
tructural architecture of the specific tumor tissue. The bioink can have
ultiple types of patient-derived malignant and healthy cells (cancer
nd stromal bioinks). The cells are mixed with other components of
ioink (biopolymers, media and growth factors) at the ratio required to
imic the in vivo tumor architecture and microenvironment [110] . The
ioinks are then extruded to print the construct as per CAD design. Re-
ent approaches such as immersion printing, are beneficial in developing
umor constructs in multi-well plates therefore increasing the through-
ut of personalized drug screening [111] . Integrated microscale continu-
us optical 3D bioprinting can also be used to generate tumor constructs
n multi-well plate formats [112] . These techniques facilitate the devel-
pment of constructs with varying spatial geometries with the added
dvantage of reproducibility. Once the complete model is printed layer
y layer, the construct is exposed to final crosslinking (photocrosslink-
ng or ionic crosslinking depending upon the hydrogel composition) and
hen maintained in a suitable culturing medium for maturation [113] .
iochemical gradients in tumor tissues greatly impact cellular processes
uch as cell adhesion, cell migration, c ell proliferation, differentiation
nd angiogenesis. To provide a chemical gradient to simulate the proper
aturation of bioprinted construct, multiple active agents can be loaded
s multiple layers with varying layer spacing [114] . 
In vitro tumorigenesis facilitated by cell division, proliferation and
ifferentiation during maturation of bioprinted constructs is a critical
tep in the post ‐printing stage on cancer constructs. Achieving rapid
aturation of bioprinted construct is key especially when these are uti-
ized for screening of personalized anti-cancer therapies. This is time
ensitive and requires identification of the most suitable chemotherapy
egimen that could be administered to the cancer patients. Nevertheless,
ccelerated tissue maturation is challenging and further research and
ptimization is required to progress the development of personalized
ioprinted tumor constructs for precision chemotherapeutic screening.
ast studies indicated that tissue maturation can be achieved in static
ulture systems to some extent [115] . Recently it has been reported that
ncubation of tissue spheroids for different time periods affected tissue
usion kinetics [116] , which is an important factor to consider with mat-
ration of bioprinted cancer constructs. Incubation of tissue spheroids
n hanging drop cultures for long duration appears to stimulate tissue
ohesion and maturation along with improved accumulation of ECM
olecules [117] . 
Several physicomechanical measurements and biological assays are
equired to properly characterize bioprinted cancer constructs before
sing these for personalized drug testing. Stiffness of the construct can
e measured by nanoindentation using an Atomic Force Microscope
AFM) [20] . Scanning electron microscopy of fixed and dried construct
an be performed to characterize the topographical features of the bio-
rinted construct. It is also key to verify the viability of cells present
ithin the bioprinted construct promptly after bioprinting and through-
ut the course of in vitro maturation and maintenance. Viability of dif-
erent types of cells within the constructs can be tested by calcein-AM
ased staining which can label live and dead cells by staining live cells
reen. Depending upon the 3D model, different types of immunohisto-
hemistry or immunofluorescence assays can be performed to under-
tand the expression of various proteins important in the development
nd maintenance of cancer progression, synthesis of ECM components
nd membrane proteins [52] . Once the bioink composition, process of
abrication, and maturation conditions, are optimized, developed tumor
onstruct can be used for drug testing. 6 Personalized bioprinted tumor constructs after maturation can be
sed to test an array of potential chemotherapeutic agents. In static cul-
ure systems, the chemotherapeutic agents can be administered to a tu-
or construct within the cell culture medium to determine the effects
n cell viability and tumor growth reduction. Bioprinting can be per-
ormed in multi-well plates, generating large numbers of homogeneous
rganoids thus increasing the throughput of screening [ 111 , 118 ]. In
 more realistic bioprinted tumor constructs, chemotherapeutic agents
an be administered through built-in micro- channels that mimic tumor
asculature [119] . Tumor constructs can also be printed on microfluidic
hips or integrated with similar platforms to automate the screening as-
ay and perform the analysis of a number of drugs simultaneously as
ell as determine the response and mechanism in real-time [ 120 , 121 ]. 
. Cancer-specific bioprinted models for precision chemotherapy 
creening 
.1. Bioprinted breast cancer models 
Breast cancer is the most frequently diagnosed cancer in women
orldwide, with approximately 2.09 million new cases and 627,000
eaths in 2018, estimated by the WHO [122] . Most cancer-related
eaths result from breast cancer metastasis to vital organs indicating
he importance of early diagnosis and treatment [123] . Along with ma-
ignant cells, stromal cells of breast cancer also greatly influence the
rogression of tumor by altering the cells phenotypes, secreting signal-
ng molecules and reorganizing themselves to support tumor invasion
109] ( Fig. 3 -A). Moreover, immune cells within the stroma also play
mportant roles in modifying the tumor microenvironment [124] . For
xample, inflammation and angiogenesis are two major factors influ-
ncing the ECM matrix elements of tumor microenvironments [125] .
hus, reliable breast cancer models should be based on patient-derived
ancer cells and surrounding healthy cells (e.g. fibroblast, immune, ep-
thelial and endothelial cells) to recapitulate a functional in vivo tu-
or microenvironment. Initial studies in this field were focused on the
evelopment of bioprinted breast cancer spheroids using widely avail-
ble breast cancer cell lines and synthetic hydrogels [126] . Bioprint-
ng based on cellular spheroid construction was demonstrated by Ling
t al. using MCF-7 breast cancer cells and gelatin hydrogel showing
he advantage of uniform cell distribution in spheroids and the poten-
ial for anticancer drug screening [127] . Swaminathan et al. developed
ioprinted construct using pre-formed spheroids of human breast ep-
thelial cell lines [128] . They also developed bioprinted constructs us-
ng individual cell loaded bioinks for comparison. Pre-formed breast
pheroids maintained their architecture, viability and cellular function
fter bioprinting. However, individual breast cells only spontaneously
ormed spheroids in Matrigel-based bioink. Moreover, spheroids-based
onstructs showed higher resistance to paclitaxel than individual cell
ased bioprinted constructs, which could be linked to enrichment in
ancer stem cells within spheroids. Mollica et al. reported the successful
evelopment of bioprinted organoids and tumoroids using a 3D hydrogel
omprised ECM proteins [129] . It was noted that co-culturing the breast
ancer cells (MDA-MB-231) with osteoblasts or mesenchymal stem cells
MSCs) in bioprinted constructs improved the secretion of VEGF com-
ared to mono-culture of cancer cells [130] . Moreover, the breast cancer
igration potential was improved in newly developed 3D bioprinted
odels compared to 2D tumor models. Additionally, co-culturing of
131] adipose- [20] or bone marrow- derived [132] MSCs with cancer
ells enhanced the spheroid colony formation within 3D bioprinted con-
tructs ( Fig. 3 -B). Recent studies demonstrated that bioprinting of the
ells in a co-culture with adipocytes resulted in morphological changes
nd differences in cell localization within printed structures [131] . In-
egration of vascular networks within bioprinted constructs would be
 closer step towards the development of physiologically relevant en-
ineered cancer tissues. A proof-of-concept of bioprinted vascularized
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Fig. 3. Bioprinted breast cancer models. A. The important components within breast cancer microenvironment including interstitial matrix and the basement 
membrane proteins (left circle). The signaling from the ECM proteins is propagated via multiple signaling pathways, both simultaneously and independently (right 
circle). B. 3D bioprinted breast cancer model with breast cancer cells (21PT cells) in the middle and surrounding Adipose-Derived Mesenchymal Stem Cells (ADMSCs). 
(a) Scheme of bioprinting setup that uses two types of cell laden bioinks. Representative immunofluorescent staining for vimentin (red), E-cadherin (E-cad, green), and 
nuclei (blue) of 21PT and ADMSC within bioprinted constructs. (b) Representative immunofluorescent staining of vimentin (red), caspase 3 (green), and nuclei (blue) 
of 21PT and ADMSC cells after 21-day culture and with the addition of different concentration of doxorubicin (DOX) for another 3-day culture. (c) Representative 
immunofluorescent staining for aSMA (red), LOX (green), and nuclei (blue) of 21PT and ADMSC within bioprinted constructs after 21-day culture and with the 
addition of different concentrations of DOX for another 3-day culture. Figure A is reproduced from Ref. [109] with creative commons attribution (CC BY) license. 




































o  umor constructs was provided by Cui et al in their interesting research
n 3D printed breast-bone metastatic model [133] . Liu et al. developed
 human breast tumor model with physiologically relevant embedded
ymphatic vessels by sacrificial bioprinting [134] . This offers promise
or developing and screening personalized tumor anti-lymphangiogenic
herapies in the future. Recent investigation suggested that the gene al-
erations during bioprinting are evident demonstrated by changes in the
xpression of LUCAT1, IL6, CCL26, and NRN1L genes and phosphoryla-
ion of critical oncogenic drug resistance pathways in breast cancer cells
n thermal bioprinted constructs [135] . Understanding such changes at
he molecular level in bioprinted constructs would help to develop mod-
ls that mimic human tumor tissues. A proof-of-concept study utiliz-
ng bioprinted breast cancer constructs was reported by Li et al. [136] .
sing a hydroxyethyl cellulose/alginate/gelatin hydrogel and MCF-7-
ased spheroid bioprinted construct, the anti-breast cancer activity of
hosphoramidates (13 amino acid-containing flavone) was examined
nd the results indicated that alanine structure induced a stronger drug
esistance than phenylalanine in the MCF-7 cells. The development of
dvanced screening and drug testing platforms for precision medicine7 pplications has progressed significantly based on the advancements in
D co-cultured breast cancer models [137] . 
.2. Bioprinted brain tumor models 
About 10–40% of brain tumors are metastatic at the time of diag-
osis and hence when developing in vitro models of brain tumors, this
hould be taken into the account [138] . Bioprinted brain tumor con-
tructs for drug screening/personalized treatment regimens can be par-
icularly beneficial for glioblastoma (GBM), the brain tumor type that
hows resistance to a number of chemotherapeutic agents [ 139 , 140 ]. In
ddition to the overall poor response of GBM to chemotherapy, hetero-
eneity within these tumors and inter-patient variations in treatment
esponse [141] are also having negative impact on patient outcomes.
his unmet clinical need could be addressed through the development of
ersonalized therapeutic approaches and novel therapies that are tested
n patient-derived bioprinted constructs with a potential to improve pa-
ient survival rates [ 142 , 143 ]. Initial studies that focused on the devel-
pment of brain tissues using 3D bioprinting technique with different

































































































































ypes of brain cancer and healthy cells including stem cells provided a
roof-of-concept for the generation of bioprinted brain tumor constructs
onstituting heterogeneous group of cells [21] . These models can reli-
bly recapitulate in vivo tumor microenvironment and represent promis-
ng personalized GBM platforms for chemotherapeutic screening. The
esults from a study investigating temozolomide treatment for GDM,
howed that 3D tumor models containing glioma stem cells were more
esistant to temozolomide treatment compared to 2D monolayer, thus
ikely recapitulating physiological tumor response more closely [142] .
ang et al. developed bioprinted GBM tumor models using glioma cell
ine U118 within the core of the construct and glioma stem cell, GSC23,
n the shell of hydrogel microfibers by coaxial extrusion bioprinting
echnique [144] ( Fig. 4 -A). Developed constructs were able to better
imic glioma microenvironment, which was supported by observed
esistance to chemotherapeutic agents and higher expressions of tu-
or invasiveness markers including vascular endothelial growth factor
eceptor-2 (VEGFR2), matrix metalloproteinases (MMP2, MMP9) and
6-methylguanine-DNA methyltransferase (MGMT). Another interest-
ng study from the same group indicated that 3D bioprinted glioma stem
ell-containing constructs showed the expression of tumor angiogenesis-
ssociated genes and higher vascularization potential [35] ( Fig. 4 -B).
i et al. demonstrated that 3D bioprinted GBM constructs composed of
atient-derived cancer cells, vascular endothelial cells and brain tissue-
erived ECM into concentric-ring structure are reliable platforms of
BM microenvironment in terms of structural, biochemical and biophys-
cal characteristics [145] . A key feature of GBM is high degree of vas-
ularization [146] , and this uncontrolled tumor vascularization aids in
apid progression and invasion of this tumor [147] . Thus, chemother-
peutic approaches targeting GBM are focused on the treatments capa-
le of blocking key mechanisms of tumor angiogenesis [148] . Hence,
o study the potential of chemotherapeutic agents in GBM, it is key to
stablish a well-connected vasculature in bioprinted cancer construct
149] . Moreover, it has been reported that a subtype of glioma stem cells
ithin the GBM tumor can differentiate into endothelial cells promot-
ng angiogenesis [150] . Use of such tumor angiogenic cells in bioinks
an generate a vascular network within the construct. This was repli-
ated by stimulating angiogenesis through cultured GSCs secreted fac-
ors present in the cell medium [ 32 , 35 ]. A recent study managed to re-
apitulate the heterogeneous glioblastoma tumor microenvironment in
ioprinted constructs using an array of cancer and stromal cells includ-
ng MM6 monocyte/macrophages, U87MG glioblastoma cells, glioblas-
oma stem cells, microglia and glioma associated stromal cells (GASCs)
roviding a more realistic chemotherapeutic response [151] ( Fig. 4 -C).
n an interesting study, a 3D ‐bioprinted mini ‐brain incorporated with
lioblastoma ‐associated macrophages (GAMs) and glioblastoma tumor
ells was created to study the phenotypic alteration in both cancer cells
nd macrophages using a a two-step bioprinting process [21] . This study
learly demonstrated that this 3D ‐bioprinted tumor model is not only
ble to mimic intact GBM, but also applicable to other types of cancers
nd can be used as a tool to improve the understanding of tumor biology
s well as for testing chemotherapeutic drug efficacy. An immersion bio-
rinting technique has also been practiced in patient-derived GBM and
arcoma biospecimens, which can mitigate the limitations of patient de-
ived tumor organoids(PTO) for drug screening [111] . 
.3. Bioprinted skin cancer models 
Skin cancer or melanoma is one of the most common forms of can-
ers especially in Caucasian people consisting of different cancer types
ncluding non-melanoma skin cancer (NMSC), malignant melanomas
MM), Merkel cell carcinomas (MCC), basal cell carcinomas (BCC) and
utaneous squamous cell carcinomas (cSCC), that affects over 300,000
eople annually across the globe [152] . Laser-assisted bioprinting tech-
ique was used to develop a first batch of bioprinted artificial skin
onstructs in a collagen matrix embedding multiple layers of fibrob-
asts and keratinocytes [153] . In order to develop adequate vascular-8 zation, micro-channels were generated from alginate bioinks using a
D bioprinter [154] . The 3D bioprinted modified constructs were able
o form perfusable vasculature within dermal and epidermal skin lay-
rs [155] . Similarly, spheroids based on primary melanoma cells or
ell lines are also good candidates for investigating the effectiveness
nd mechanism of personalized treatments in melanoma. Encapsulation
f stroma cells within 3D constructs mimic accurately tumor microen-
ironment as these cells secrete growth factors and ECM components
eeded for the tumor growth and migration potential. Melanoma co-
ulture models frequently use fibroblasts, immune cells, and endothelial
ells, in combination with melanoma cells. The co-culture models can be
eeded both following cancer MCTS formation or simultaneously with
umor cells in non ‐adherent conditions [ 156 , 157 ]. In another important
tudy, 3D human skin equivalents (HSE) and melanoma skin equivalent
MSE) from human de ‐epidermized dermis (DED), keratinocytes and fi-
roblasts were utilized for the study of vertical migration and invasion
f myeloma cells. The developed skin constructs resemble human skin
ith pronounced stratification of dermis and epidermis and a basement
embrane. Interestingly, the keratinocytes cells confined themselves to
pidermis and fibroblasts differentiated into dermis within the HSE and
SE [ 158 , 159 ]. A combination of TRAIL (tumor necrosis factor-related
poptosis-inducing ligand) and ultraviolet-B radiation (UVB) or cisplatin
ed to the development of an organotypic human skin-melanoma model
ith a potential to be used as a platform for precision medicine ap-
roach and tailor treatment regimens [160] . Before the development
f 3D HSEs, Hill and colleagues developed a representative skin model
ased on the human fibroblasts laden within an inert porous scaffold
here the myeloma cells move radially and vertically during tumor pro-
ression [161] . As indicated in a preliminary study, 3D bioprinting tech-
iques can be used to fabricate skin constructs of varying pathophysio-
ogical features, either as non-vascularized or vascularized forms, and in
 multi-well platform to enable drug screening [162] . Recent advances
ike immersion bioprinting of patient derived sarcoma and its use in
rug screening will be a game changer in personalized cancer therapy
111] . 
.4. Bioprinted colorectal cancer models 
Colorectal cancer (bowel cancer, colon cancer, or rectal cancer) is
ssociated with one of the poorest survival rates and it is often diag-
osed at the metastatic stage [163] . Timely identification and treatment
f colorectal cancers can prevent the spread of tumor to surrounding
reas and metastases to distal organs. Colorectal cancer mostly arises
rom dysplastic adenomatous polyps [164] . Adenocarcinoma is the most
ommon type of colorectal cancer comprising around 95% of the cases
164] . Intestinal spheroid models and organoid models with human
olon adenocarcinoma, adenoma, and Barrett’s epithelium were devel-
ped showing promising cancer models [165] . The stem cell-like prop-
rties of these organoids can be propagated and stored in a biobank
or future application in pre-clinical and clinical research [166] . Re-
ent advances in the techniques of 3D bioprinting have enabled re-
earchers and clinicians to develop 3D colorectal models that mimic
he exact mechanisms of cancer initiation, growth and invasion and fo-
us on personalized drug treatments. In colorectal carcinoma, the suc-
ess of personalized drug treatment is reliant upon accurate diagnosis
ased on histopathological and imaging assessments of the patients, the
ikelihood of tumor recurrence following tumor debulking and the an-
icipated response to adjuvant systemic chemotherapy. It was reported
hat developing 3D bioprinted tumor models by encapsulating colorec-
al cells within alginate polymer bioinks reduced the hypoxic regions
ompared to spheroid cultures, thereby showing better suitability for
recision medicine screening application [ 167 , 168 ]. Furthermore, re-
ent advances utilizing induced human pluripotent stem cells (iPSCs)
howed this approach could generate intestinal organoids for the devel-
pment of patient specific in vitro models and personalized drug screen-
ng [169–171] . 
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Fig. 4. Bioprinted brain tumor models: A. (a) Microscopic images of U118 cells collected from hydrogel fibers and U hydrogel microfibers after temozolomide 
(TMZ) treatment, dead cells (red) accumulated into clusters. (b) Cell viability after treatment with TMZ. B. (a) SEM images of cell clusters from suspension culture 
and from 3D bioprinted constructs. (b) The expression of angiogenesis-related genes (CD31, VEGFR2, HIF-1 𝛼 and CD133) in 3D bioprinted tumor constructs and 
suspension culture. The percentage of CD133 + cells in 3D bioprinted scaffolds in comparison to suspension culture. C. (a) Drug dose response of glioblastoma cells 
in 3D bioprinted models. U87MG or G7 cells were cultured in 2D or 3D printed in RGDS-Alginate after treatment with increasing concentrations of either cisplatin 
or temozolomide (TMZ) for 72 hours. (b) U87MG-EGFP and G7- EGFP, were 3D printed either alone or in co-culture with either MM6 cells, aMM6 cells or primary 
human microglia. Fig. A is reproduced from Ref. [144] with the permission of Elsevier. Figure B is reproduced from Ref. [35] with the permission of Elsevier. Fig. C 









c  .5. Bioprinted cervical cancer models 
Cervical cancer continues to be the leading cause of death in women
espite recently introduced vaccination and screening, hence with an ur-
ent need for improvement in personalized screening, and treatment ef-9 orts [172] . The potential precursor of cervical cancer is cervical intraep-
thelial neoplasia. Cervical cancer is divided into two main subtypes
amely squamous cell carcinoma and adenocarcinoma that account for
0% and 25% cervical cancer cases, respectively [173] . Squamous cell
arcinoma develops within the thin flat cell lining of cervix hence,






























































































































nown as squamous cell carcinoma, which later projects into vagina. On
he other side, adenocarcinoma is found in cervical canal line close to
olumn shaped glandular cells. For tumorigenesis study and anti-cancer
rug screening, bioprinted models of cervical cancer have showed sub-
tantial improvement and utilization in mimicking the physiological en-
ironment. In this context, HeLa cells were loaded in a hydrogel scaf-
old comprised of gelatin, alginate, and fibrinogen myofibrils to bio-
rint 2D and 3D tumor construct of cervical cancers [31] . HeLa cells
eveloped into 3D spheroids in 3D cultures while monolayer cell sheets
ere formed in 2D culture. In addition, HeLa cells showed a marked
ncrease in the expression of MMP proteins in 3D bioprinted models,
hich are capable of degrading ECM components and these 3D models
ere more sensitive to paclitaxel treatment. The findings of this study
emonstrated the benefits of these 3D bioprinted in vitro cervical can-
er models for investigating mechanisms and treatment options for pre-
enting cervical cancer progression. It was observed that HeLa cells mi-
rated to different extents depending on the channel diameter and no ef-
ects were reported on fibroblast migration [174] . Transforming Growth
actor- 𝛽 (TGF- 𝛽) induced (EMT) in an advanced bioprinted cervical
umor model shows promising results for developing future therapeu-
ic strategies towards preventing or treating cervical tumor metastasis.
 HeLa/hydrogel grid construct comprising alginate, gelatin, Matrigel
nd HeLa cells showed rapid proliferation, formation of spheroids and
isplayed tumorigenic feature in the 3D-printed construct. The down-
egulation of epithelial marker, E-cadherin, and up-regulation of mes-
nchymal markers including snail, vimentin and N-cadherin, were re-
orted in the 3D-printed model with the supplementation of TGF- 𝛽. Fur-
hermore, the TGF- 𝛽 induced EMT was inhibited following treatment
ith disulfiram and EMT pathway inhibitor C19 in a dose-dependent
anner [175] . Despite significant developments in cervical cancer pre-
ention, diagnosis, and treatment, there are still disparities in patient
utcomes, hence further research efforts are required for implementa-
ion of precision medicine, which may be addressed through utilization
f patient-specific bioprinted cervical cancer constructs for drug screen-
ng and mechanistic insight [176] . 
.6. Bioprinted pancreatic cancer models 
Pancreatic adenocarcinoma is the second most lethal cancer in the
orld. Advance stages of pancreatic cancer have very poor prognosis
ith a five-year survival rate ∼2–5% cases [177] . There are differ-
nt types of pancreatic cancers with pancreatic ductal adenocarcinoma
PDAC) being the most common (95%) type [178] . Within the pancre-
tic carcinomas, pancreatic cancer cells are surrounded by a scar-like
ense fibrous tissue, which acts as a barrier containing protective pro-
eins that abrogates body’s own anti-cancer defense mechanisms and
he effectiveness of drug treatments. Therefore, there is an unmet clini-
al need for representative models that could help our understanding
nd provide insight into the effectiveness of different treatment reg-
mens, particularly for PDAC. These models should mimic in vivo tu-
ors and microenvironment and include strategies for recapitulating
urrounding fibrous tissue containing barrier proteins [179] . It is well
ocumented that stromal cells in pancreatic cancer account for more
han 80% of the total tumor volume and secrete a number of signaling
olecules including fibroblast growth factor (FGF), epidermal growth
actor (EGF), VEGF, TGF 𝛽 and insulin-like growth factor Ⅰ (IGF- Ⅰ ) as well
s matrix metalloproteinases (MMPS) [180] . Overexpression of these
ignaling factors fuels the progression of pancreatic cancer by enhanc-
ng cell proliferation, migration and invasion [ 181 , 182 ]. Physiologically
ertinent 3D organotypic models could be beneficial for better under-
tanding of the stromal and cancer cell behaviors and cell-cell interac-
ions [183–185] . Hanging drop technique has been utilized previously
o create 3D tumors in vitro . Most pancreatic cancer cells do not form
ohesive and compact spheres when the original hanging drop method
s used. However, a modified hanging drop method following addition10 f methylcellulose polymer was capable of growing uniform and re-
roducible spheroids for all five of the tested human pancreatic can-
er cell lines; Panc-1, BxPC-3, Capan-1, MiaPaCa-2, and AsPC-1 [186] .
anaka et al. developed 3D bioprinted constructs of liver fibrosis model
y using pancreatic stellate cells (PSCs), main resident cells of pancre-
tic cancer desmoplasia. In these 3D pancreatic tumor models, there
as a significant improvement in collagen deposition and orientation
f fibronectin fibril which was considerably remodeled by the influence
f PSCs without any impact on fibroblasts [187] . Cancer-associated fi-
roblasts (CAFs) found frequently in tumor microenvironment have a
efinite function in tumor development and drug efficacy [188] . Hou
t al. in their study, fabricated tumor models using two types of CAFs
nd two different pancreatic cancer cells derived from human pancre-
tic tumor tissue and were able to produce organoids in the absence of
CMs using the 3D bioprinting technology [189] . Another study used
agnetic force dependent bioprinting technology for the development
f high-throughput screening (HTS) pancreatic 3D cancer constructs us-
ng a non-adherent standard flat-bottom well cell culture plates [190] .
regon Health & Science University filed a patent on the development
f bioprinted tumor model composed of both stromal and tumor equiv-
lents [23] . Hakobyan et al. developed 3D pancreatic cell spheroid plat-
orms employing laser-assisted bioprinting and exemplified their mor-
hological changes over time through image analysis and phenotypic
haracterization [191] . The initial stage of PDAC development can be
eplicated using bioprinted spheroids based on a combination of aci-
ar and ductal cells. Overall, standardized and optimized printing pa-
ameters are important to adapt successful 3D printed tissues and or-
ans, which can have a significant role in personalized drug develop-
ent process. Continuing challenges of 3D bioprinting, comprising bio-
ompatible material requirements, suitable cell sources, neovascular-
zation, and autonomous maturation with continuous functionality of
he constructs, still needs to be improved for its wider clinical applica-
ion. 
.7. Bioprinted ovarian cancer models 
Ovarian cancer is the seventh most lethal cancer in women [192] .
igh grade serous ovarian cancer (HGSOC) is the most widespread and
ggressive form leading to the majority of advanced ovarian cancer cases
193] . Despite improvements in diagnosis and treatments, 5 years sur-
ival rate in ovarian cancer patients is still very low, ∼30% [194] Over-
ll, there are two main types of ovarian cancers classified as Type I and
ype II ( Fig. 5 -A,B). Among the subtypes of ovarian cancer cells, ep-
thelial tumors are known to have low malignant potential; this subtype
s more common in young women. In type-I epithelial ovarian cancer
ype, precursor lesions are clearly defined, whereas in Type-II lesions,
alignant cells may arise from the tubal and/or ovarian surface epithe-
ium [195] . The discovery of tumor diversity and subsequent advances
n genomic technologies over the last few years have led to molecu-
ar classification of ovarian cancer that have informed the design of
ew experimental models including 3D bioengineered systems, for early
nd accurate detection and to develop better therapeutic interventions
 105 , 196 ]. An example of this is the use of MRC-5 fibroblasts and hu-
an ovarian cancer (OVCAR-5) cell models that were bioprinted by
roplet-based bioprinting (DBB) on Matrigel to form high-throughput,
eproducible multicellular constructs with controlled spatial environ-
ent ( Fig. 5 -C) This approach thus provided a platform to minimize
he size of macro-scale 3D culture model and can serve as an innova-
ive platform comprising tumor and stromal cells microenvironments
or a high-throughput and robust personalized drug screening [197] .
ee et al. developed 3D ovarian in vitro tumor model composed of ep-
thelial ovarian cancer (EOC) cells, reporting a substantial transition in
istological features of 3D constructs compared to 2D tumor models,
hich are hallmark features of primary tumors. 
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Fig. 5. Bioprinted ovarian cancer model: A. The major subtype of ovarian neoplasm histologically divided in two subclassifications: Type I ovarian cancer 
contains low-grade, slow developing neoplastic cells that genuinely comes from boarder line tumors, which itself arises from ovarian surface epithelium, cysts, or 
endometriosis. On the other hand, Type II neoplastic cells are high-grade and fast developing. Typically, at the time of diagnosis this type is completely diffused 
beyond the ovary. B. Histology of A2780 and OV2008 cells when grown in 3D and as xenografts. Histological features of 3D and xenografted cells are highly similar. 
C. GFR Matrigel with formation of 3D acini TM . Printed OVCAR5 cells on Matrigel TM matrix and growth in culture medium. (a) Images of 7 days later after printing 
showing two photon autofluorescence with 3D structure of 3D acini formed by ovarian neoplastic cells. (b) Image showing the OVCAR5 and MRC-5 cells at 8 th day of 
coculture. (c) Acini growth kinetics after patterning: the number of acini changes as a function of initial number of cells per droplet. Average acini size increases with 
culture time. Figure A is reproduced from Ref. [196] with Creative Commons Attribution license (CC-BY). Fig. B is reproduced from Ref. [198] with the permission 



















s  .8. Bioprinted lung cancer models 
Based on histological classification, there are two main types of lung
ancers- I) small cell lung cancer and II) Non-small cell lung cancer
199] . For advance management and estimating the prognosis, these
lassifications are very important. Adenocarcinoma comprise approxi-
ately 40% of lung cancers, which arises from peripheral lung tissue.
ong-term smoking and other environmental contaminants are the main
auses of lung cancer. Despite substantial advances in early diagno-
is and improved interventions, the 5-year survival rate is only 15%11 200] . Therefore, there is an unmet clinical need for the development
f better diagnostic and treatment strategies. In order to achieve this,
etter understanding of the molecular mechanisms are required espe-
ially in terms of cancer cell signaling. 3D tumor models of adenocar-
inoma containing decellularized extracellular matrices and hydrogels
ormed commonly from collagen and alginate, or other polymers have
een used in lung cancer studies for these purposes [201] . These 2D and
D tumor models produce distinct phenotypic and genotypic changes in
ells. Mazzocchi et al. established 3D tumor models with lung cancer
pheroids embedded within hydrogel scaffolds and encapsulating the
































































































































m  pecific cell types and pleural effusion aspirates from biopsy samples
rom a large number of lung cancer patients [202] . It was also demon-
trated that placing the cells into organoids created anatomically rele-
ant structures in addition to showing adenocarcinoma specific behav-
ors. An interesting study indicated that tuning of rheological properties
f sodium alginate-gelatin hydrogel improves the printability and via-
ility of non-small cell lung cancer patient derived xenograft cells and
ancer associated fibroblasts co-cultures, allowing for 3D spheroid de-
elopment within the printed construct [203] . The spheroids exhibited
umor-specific markers (e.g. vimentin and 𝛼-SMA), indicating cellular
rosstalk and its potential application in high-throughput drug screen-
ngs. Wang et al. used 3D bioprinted scaffolds to study lung cancer
etastasis formed from gelatin–sodium alginate laden with A549/95-D
ung cancer cells [204] . Thus, bioprinted tumor models developed us-
ng organoids from patient-derived tumor cells of pleural effusion fluid
xhibit in-vivo-like anatomy. Such new cancer models can be utilized
or understanding the pathogenesis of the lung cancer, test various drug
ombinations and novel therapies as well as identify specific biomark-
rs of response. All of these will lead to precision medicine and better
utcomes for the patients. 
.9. Bioprinted liver cancer models 
Hepato-cellular carcinoma (HCC), the fifth most common malignant
ancer represents about 90% of primary liver cancers and constitutes
 major global health problem [205] . For all stages combined, the sur-
ival rate of liver cancer patients is ∼ 18% [200] . Liver cancer has a
oor prognosis owing to delayed diagnosis and thus limited treatment
ptions. Rodent models do not fully simulate the complex human can-
er phenotypes due to variations in hepatocellular functions of differ-
nt species, impeding the progress in drug development for this can-
er [ 206 , 207 ]. Furthermore, there is also a lack of models that accu-
ately represent patient-to-patient variation and heterogeneity of hu-
an liver cancer tissues. Various 3D bioprinting approaches have been
sed to develop biomimetic liver tissue constructs that can recapitu-
ate native liver tissue microenvironment, vasculature and precise spa-
iotemporal signaling [ 208 , 209 ]. Initial studies focused on the print-
ng of 3D constructs encapsulated with hepatocyte-like cells in hydrogel
ioinks (e.g. calcium crosslinked alginate) to generate 3D liver tissue
onstructs ( Fig. 6 A). Since liver disease progression and chemotherapeu-
ic drug response vary between individuals personalized in vitro human
iver cancer model is a highly promising approach to better understand
he disease mechanism, and serve as a drug screening platform, even-
ually improving the treatment of disease [210] . An interesting study
hat used rapid light-based 3D bioprinting process, a liver decellular-
zed ECM-based construct for HCC progression in a cirrhotic mechanical
nvironment showed a higher expression of invasion associated mark-
rs in the HepG2 cells of bioprinted model [211] . In a study by Sun
t al., a 3D bioprinted model with HepG2 cells was developed and com-
ared with 2D cultured tumor cells [212] . Results showed a remarkable
mprovement in the expression of tumor-related genes including ALB,
FP, CD133, IL-8, EpCAM, CD24, and TGF- 𝛽 genes in 3D bioprinted
odel. Also, large variations in drug resistance genes in response to
ntitumor drugs and differences in gene expression related to hepato-
yte function and tumor was observed between bioprinted models and
D counterparts ( Fig. 6 B). A bioprinted tumor construct developed us-
ng patient-derived intrahepatic cholangiocarcinoma cells and gelatin-
lginate-Matrigel TM showed colony forming ability, high proliferation
nd survival [78] . Gene expression studies of the constructs showed the
resence of higher level of cancer/stemness associated cellular markers,
atrix metalloproteinase and EMT regulatory proteins indicating the
ormation of an invasive and metastatic type of cancer microenviron-
ent in the construct. Likewise, a 3D bioprinted liver cancer model com-
rising of HepG2 cells and sodium alginate/gelatin/fibrinogen hydrogel
as developed [213] . Further, upon treatment with different anti-cancer
rugs, such as 5-Fluorouracil, mitomycin and both, 3D models exhib-12 ted substantially different HepG2 cell behaviors compared to 2D cell
odels indicating the closer physiological relevance of bioprinted liver
ancer models for in vitro drug screening. A novel 3D biomimetic HCC
odel composes fibrotic stromal compartment and vasculature was de-
eloped, which can mimic bio-physical properties of a fibrotic, cirrhotic
nd HCC liver. This model showed chemotherapeutic drug resistance
ommonly seen in HCC patients. This 3D tumor construct could provide
 reliable new platform to investigate multifocal HCC that contribute
o early stages of cancer metastasis [214] . Also, a 3D printing model
f intrahepatic vessel was developed with the application in a naviga-
ion surgery of hepatocellular carcinoma and provided an early proof-of-
oncept for further development of vessel like structures in bioprinted
iver cancer constructs [215] . Both HCC and heterogeneous HCC/human
mbilical vein endothelial cells combinations were bioprinted in multi-
ell plates to utilize the advantage of in vivo tumor heterogeneity and
igh throughput chemotherapeutic testing [112] . These studies indicate
mportant potential applications of 3D bioprinting technology in liver-
elated biomedical fields for studying drug discovery, toxicology, and
ther pre-clinical applications. 
. Challenges and prospects 
Limitations of current in vitro and in vivo cancer models to recapit-
late the genetic makeup, molecular biology, and physiology of cancer
ells in human tumour tissues impedes their applicability in the screen-
ng of chemotherapeutic drugs and precision medicine. Despite signif-
cant progress that has been made in the development of a number of
ew anti-cancer therapies using traditional cancer models, these sys-
ems have limited applicability in screening of personalized treatments
s these are unable to reliably reproduce the heterogeneity of tumour
issue and the variation in cancer molecular and cellular characteris-
ics from individual patients. In this context, 3D constructs containing
atient-derived cells that are propagated in vitro within similar microen-
ironment as human in vivo tumours, are more reliable for generat-
ng personalized disease models. Although there has been a substantial
rogress and emerging potential of bioprinted cancer models for these
pplications, a number of challenges still remain, limiting translation to
linical and industrial applications. Although large scale manufacturing
f bioprinted constructs is still in its infancy, manufacturers including
ellink and their partners, Prellis Biologics, are in the process of devel-
ping bioprinting equipment that can potentially address the require-
ents of industry and the clinic. Holograph X bioprinter is intended
o facilitate the in-lab manufacturing of vascularized tissue constructs
or organ transplant, via holographic projection printing. Bioprinting
f patient-derived tumour constructs for screening of anticancer agents
or the purpose of precision medicine is still in the development and
t will take a number of years before it can be used in the clinical set-
ing. From the very beginning, these technologies should comply with
he good manufacturing practice (GMP) standards and the regulatory re-
uirements, in order to standardize and optimize the bioprinting process
f patient-specific tumours. Future studies should focus on the devel-
pment, fabrication, and application of bioprinted tumour constructs in
ompliance with GMP standards. These bioprinted platforms should also
e adapted accordingly for high throughput screening of chemotherapy
nd other anti-cancer agents by taking into the account the ease of use
nd the cost. Hence, future research should also focus on the rapid and
utomated determination of cellular parameters including cell viability
nd cell cycle within the 3D construct in real-time. Integration of organ-
typic constructs within simulated physiology of microfluidic platforms
re challenging with the potential to incorporate all the required char-
cteristics of human in vivo tumours. 
Published evidence in the field of bioprinted cancer models indicates
hat bioprinted cancer models are highly promising platforms for eval-
ation of personalized anti-cancer treatments. Nevertheless, there are
till substantial gaps in the knowledge in terms of various aspects of tu-
our bioprinting including rapid fabrication of 3D cancer models, their
R. Augustine, S.N. Kalva, R. Ahmad et al. Translational Oncology 14 (2021) 101015 
Fig. 6. Bioprinted liver cancer models: A. (a) Schematic of the combinatorial printing process for Alginate hydrogel and hepacyte cells. (b) Fluorescence images of 
bioprinted hESC-derived hepatocytes: a 3D stack of hepatocyte-like cells printed in hydrogel, measured one hour after printing displaying live cells in green and dead 
cells in red (c) 2D cells collected from the alginate at day-23 indicating albumin expression in green and cell nuclei (DAPI) in blue. B. (a) The bioprinted model of 
hepatocellular carcinoma (3DP-HepG2) directly after printing (b) Proliferation rates of cells in 3DP-HepG2 and in its 2D counterpart (2D-HepG2) at different time 
points. (c) Dose-effect curves of cisplatin, sorafenib, and regorafenib in the 3DP-HepG2 and 2D-HepG2 models post-72 h drug treatment. Fig. A is reproduced from 















s  aintenance in vitro and cost-effectiveness for high-throughput screen-
ng and application in the low resourced clinical setting. The design and
evelopment of a fully integrated bioprinting mechanism is key for the
ommercial translation of bioprinting technology for precision medicine
urposes in small to medium size laboratories. Future studies should fo-
us on the approaches that help to miniaturize the bioprinted constructs
uitable for automated workflow systems that are less labour -intensive
nd cost-effective. g  
13 The accurate control over physicomechanical and biological charac-
eristics of a bioprinted construct is possible using advanced 3D printing
echnologies. Suitable material for bioprinting is required to precisely
e placed with the preferred spatial and temporal control. Bioprinting
echnologies like inkjet have drawbacks in terms of material viscos-
ty whereas others such as microextrusion may need materials having
pecific crosslinking mechanisms or shear-thinning properties. Nozzle
auge is one of the processing parameters determining the shear stress

































































































































o which cells are exposed to along with the time necessary for the mate-
ial to be placed to produce a 3D structure. For instance, inkjet printing
nvolves the use of materials with a rapid crosslinking time to enable
he generation of a complex 3D structure whereas microextrusion can
ake use of highly viscous materials to keep a 3D shape after deposition
ith final crosslinking that occurs following fabrication. A recent report
ndicated that thermal inkjet bioprinting has impact on gene expression
ncluding those involved in key drug resistance, cell motility, prolifer-
tion, cell survival, and differentiation. These are important factors to
onsider and monitor as part of the process of bioengineering tumour
onstructs by bioprinting. 
The cell viability, a critical factor for cancer modelling, can be af-
ected by the shear forces generated during extrusion bioprinting. Re-
ent approaches focusing on LAB methods may be a solution for main-
aining cell viability in the future, bearing in mind that photoinitiator
nd UV light used in LAB need further optimising to minimise their effect
n cell viability. Less toxic photoinitiator or visible light photocrosslink-
ng approaches may solve these issues. Several other crosslinking ap-
roaches are also used for bioprinting to provide the sufficient mechan-
cal strength and relatively long degradation rate to the bioprinted con-
truct. A wide range of natural polymers including gelatin, alginate, chi-
osan, and collagen, have been used as a bioink for printing tumour
onstructs because of simplicity of their crosslinking mechanisms. How-
ver, ionic, or chemical crosslinking agents used for hydrogel systems
an also affect cell viability and phenotype of the tumour construct. Re-
ent advancements with introduction of photocrosslinkable methacry-
oyl groups into these biopolymers is showing some progress towards
etter preservation of cell viability and phenotype. However, fine tuning
he methodologies for bioprinting cancer and stromal bioinks capable of
ecapitulating the properties of physiological tumour tissues and their
icroenvironment in adequate spatial and temporal manner needs to be
urther explored. These models can also recapitulate the heterogeneity
f the tumors using different materials and cells simultaneously within
he same bioprinted construct. As a drug screening platform, bioprint-
ng should be applicable to several cancer types including breast cancer,
BM, cervical cancer, lung cancer and ovarian cancer. 
One of the key challenges in cancer bioprinting is the difficulty
n developing well-established vascular network within tumors, which
s necessary given that tumor tissues contains large number of highly
ranched capillary networks that facilitate tumour growth. Thus, con-
ecting the bioengineered tumour tissue with surrounding stromal tis-
ue is necessary for mimicking these cellular communications that are
resent in vivo . Generating bioprinted constructs with well-developed
asculature is particularly important in GBM, tumor characterized by
ronounced angiogenesis. Unsurprisingly, a study investigating angio-
enesis within MCTS of undifferentiated melanoma cell line, NA8-
CTS, revealed that the invasion and network formation of HMEC-1
ell line within NA8-MCTS increased following co-culturing with HMEC-
 [149] . As mentioned above, it has been reported that a subtype of
lial stem cells within the tumor are able to trans-differentiate into en-
othelial cells promoting angiogenesis [150] , therefore utilizing these
atient-derived cancer cells may establish a vasculature in bioprinted
ancer construct in the presence of adequate tumor microenvironment.
lthough various vascularization approaches are used, this could be
chieved by introducing channels inside the biofabricated tissues and
llowing media to perfuse the construct and facilitate endothelial cells
nd smooth muscle cells to adhere and proliferate on the walls of chan-
els. Nevertheless, vascularization approaches still need to be investi-
ated further and optimized for specific tumour types. On the other
and, within human tumor in vivo environment, cellular secretion of
nzymes, hormones, cytokines, or other agents can influence the mi-
roenvironment of the growing tumour. Hence, all these cellular and
olecular factors need to be taken into the account when designing and
ioprinting tumor constructs. 
Although the bioprinted cancer models share a common 3D confor-
ation, each display its own intrinsic properties. For example, a variety14 f in vitro and in vivo findings have demonstrated the significance of the
nteraction between the tumour cells and host stromal cells including en-
othelial cells, fibroblasts, adipocytes, mature immune cells, and circu-
ating immune cell progenitors. Incorporation of various types of healthy
ells and specific cancer cells is a major challenge since it is far from
imply combining similar types of cells. However, recapitulating cellu-
ar communications is vital for paracrine and autocrine molecular sig-
alling that affects key hallmarks of cancer. These include interactions
ith the surrounding matrix, host cells, and receptors or ligands of both
ancer and stromal cells. For instance, CAFs that affect tumor microen-
ironment are the most common component of cancer stroma mainly
n breast and pancreatic cancer, MRC-5 fibroblasts and OVCAR-5 in hu-
an ovarian cancer cell models, a set of cancer and stromal cells includ-
ng U87MG glioblastoma cells, MM6 monocyte/macrophages, glioblas-
oma stem cells, glioma associated stromal cells (GASCs) in GBM and
PSCs in colorectal cancer models have been used for personalized drug
creening. Understanding biology of specific types of tumors well will
id the development of suitable bioprinted platforms with high predic-
ive power, capable of drugs screening and precision medicine. 
The effectiveness and purpose of tissue constructs can be designed,
nd hence improved, before it is printed using computer models. There-
ore, design stage is key for generating optimal and specific 3D cancer
issues representative of physiological tumours. Rapid developments in
ioprinting instrumentation along with progress in bioink preparation
nd bioprinting process can significantly improve the ability of the con-
truct to closely mimic cancer tissue and its reliability to test chemother-
peutic drug efficacy. Moreover, regulatory agencies should have stan-
ardized guidelines for the requirement of processes and procedures to
ccelerate the clinical translation of these bioprinted tissue models and
nable personalized treatments that will improve outcomes for the pa-
ients. 
. Conclusions 
Over the last two decades, the tools used to create 3D cell cultures,
rganoids, and other 3D in vitro models, including cell supportive biolog-
cal material and 3D bioprinting, have rapidly progressed. Conventional
ancer models have a number of limitations due to the lack of capac-
ty to mimic the complexity of tumours, thus restricting their utilisa-
ion for chemotherapeutic drug screening. Attempts to diligently mimic
he tumour microenvironment appear to be feasible with the introduc-
ion of latest technologies such as bioprinting and microfluidic chips.
ast research shows that the 3D bioprinting has a huge potential to
onstruct tissue models that can recapitulate tumour microenvironment
t molecular, cellular, and physiological level. Bioprinted breast, brain,
kin, colorectal, pancreatic, and other cancer models were highly suc-
essful in mimicking tumour anatomy, physiology, and molecular biol-
gy. Patient-derived 3D bioprinted cancer models could be successfully
sed for in vitro drug screening of anti-cancer drugs in order to develop
ersonalized treatments. Ongoing and future studies are focusing on the
evelopment of integrated microfluidic/bioprinted constructs in a lab-
n-a-chip format to minimize the cost and facilitating high throughput
esting of a large number of available chemotherapeutic agents enabling
election of the most suitable drug combination for a particular patient
nd hence personalized medicine approach. 
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